ArticleThe Journal of antimicrobial chemotherapy2026
Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe class C β-lactamase, PAC-1, was originally described as acquired in Pseudomonas aeruginosa clinical isolates from south Asia, the corresponding gene being chromosomally located and embedded within a Tn1721-like transposon. Despite its association with high-level resistance to cephalosporins and β-lactam/β-lactamase inhibitor combinations, data on its full hydrolytic profile and kinetic parameters have not yet been comprehensively characterized.
objectivesTo characterize the susceptibility profile and hydrolytic kinetics of PAC-1, with a particular focus on cefiderocol hydrolysis, and the activity of novel β-lactam/β-lactamase inhibitor combinations.
methodsThe blaPAC-1 allele was cloned into vector pUCP24 and expressed in Escherichia coli TOP10 and Pseudomonas aeruginosa PAO1, respectively. MICs were determined by broth microdilution and interpreted according to EUCAST guidelines. PAC-1 was purified, and steady-state kinetic measurements of selected β-lactams were determined. IC50 values were determined for the β-lactamase inhibitors avibactam, taniborbactam, xeruborbactam and zidebactam. WGS was performed to characterize the genetic environment of the blaPAC-1 gene.
resultsPAC-1 conferred broad resistance to penicillins, broad-spectrum cephalosporins and cefiderocol, while carbapenems remained unaffected. Kinetic analyses confirmed high catalytic efficiency against cefotaxime and aztreonam, but no hydrolysis of imipenem. Avibactam, relebactam and vaborbactam failed to inhibit PAC-1 (IC50 > 1000 µM), whereas xeruborbactam and zidebactam showed potent inhibitory activities (IC50 = 1.0 and 0.6 µM, respectively). A chromosomally located Tn1721-like transposon was identified carrying the blaPAC-1 gene in P. aeruginosa ST4936.
conclusionsPAC-1 is not inhibited by avibactam and hydrolyses a broad range of β-lactams including the novel cephalosporin cefiderocol. The combination cefiderocol/zidebactam was the most active against PAC-1. Transposon-mediated dissemination across distinct lineages warrants continued epidemiological surveillance of PAC-type β-lactamases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.